Suppr超能文献

HES1 介导的 miR-138 下调维持 NOTCH1 激活,促进肾细胞癌的增殖和侵袭。

HES1-mediated down-regulation of miR-138 sustains NOTCH1 activation and promotes proliferation and invasion in renal cell carcinoma.

机构信息

Department of Urology, The First Hospital of China Medical University, Shenyang, 110001, China.

Department of Gynecology, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, China.

出版信息

J Exp Clin Cancer Res. 2023 Mar 28;42(1):72. doi: 10.1186/s13046-023-02625-0.

Abstract

BACKGROUND

Although the aberrant activation of NOTCH1 pathway causes a malignant progression of renal cell carcinoma (RCC), the precise molecular mechanisms behind the potential action of pro-oncogenic NOTCH1/HES1 axis remain elusive. Here, we examined the role of tumor suppressive miR-138-2 in the regulation of NOTCH1-HES1-mediated promotion of RCC.

METHODS

This study employed bioinformatics, xenotransplant mouse models, ChIP assay, luciferase reporter assay, functional experiments, real-time PCR and Western blot analysis to explore the mechanisms of miR-138-2 in the regulation of NOTCH1-HES1-mediated promotion of RCC, and further explored miR-138-2-containing combination treatment strategies.

RESULTS

There existed a positive correlation between down-regulation of miR-138 and the aberrant augmentation of NOTCH1/HES1 regulatory axis. Mechanistically, HES1 directly bound to miR-138-2 promoter region and thereby attenuated the transcription of miR-138-5p as well as miR-138-2-3p. Further analysis revealed that miR-138-5p as well as miR-138-2-3p synergistically impairs pro-oncogenic NOTCH1 pathway through the direct targeting of APH1A, MAML1 and NOTCH1.

CONCLUSIONS

Collectively, our current study strongly suggests that miR-138-2 acts as a novel epigenetic regulator of pro-oncogenic NOTCH1 pathway, and that the potential feedback regulatory loop composed of HES1, miR-138-2 and NOTCH1 contributes to the malignant development of RCC. From the clinical point of view, this feedback regulatory loop might be a promising therapeutic target to treat the patients with RCC.

摘要

背景

尽管 NOTCH1 通路的异常激活导致肾细胞癌(RCC)的恶性进展,但潜在的致癌 NOTCH1/HES1 轴的精确分子机制仍不清楚。在这里,我们研究了肿瘤抑制 miR-138-2 在调节 NOTCH1-HES1 介导的促进 RCC 中的作用。

方法

本研究采用生物信息学、异种移植小鼠模型、染色质免疫沉淀(ChIP)检测、荧光素酶报告基因检测、功能实验、实时 PCR 和 Western blot 分析等方法,探讨了 miR-138-2 调节 NOTCH1-HES1 介导的 RCC 促进作用的机制,并进一步探讨了 miR-138-2 包含的联合治疗策略。

结果

miR-138 的下调与 NOTCH1/HES1 调节轴的异常增强之间存在正相关。在机制上,HES1 直接结合 miR-138-2 启动子区域,从而减弱 miR-138-5p 和 miR-138-2-3p 的转录。进一步分析表明,miR-138-5p 和 miR-138-2-3p 通过直接靶向 APH1A、MAML1 和 NOTCH1,协同损害致癌的 NOTCH1 通路。

结论

综上所述,我们的研究强烈表明,miR-138-2 是致癌性 NOTCH1 通路的一种新型表观遗传调节剂,由 HES1、miR-138-2 和 NOTCH1 组成的潜在反馈调节环有助于 RCC 的恶性发展。从临床角度来看,该反馈调节环可能是治疗 RCC 患者的有前途的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d73b/10045948/17122447a2bf/13046_2023_2625_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验